Trademark Overview
On Tuesday, November 9, 2021, a trademark application was filed for EXPRESS SCRIPTS RIGHT PRICE with the United States Patent and Trademark Office. The USPTO has given the EXPRESS SCRIPTS RIGHT PRICE trademark a serial number of 97115840. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, July 21, 2023. This trademark is owned by Express Scripts Strategic Development, Inc.. The EXPRESS SCRIPTS RIGHT PRICE trademark is filed in the Advertising, Business and Retail Services and Insurance & Financial Services categories with the following description:
Prescription drug savings services relating to employer's self-funded prescription programs to provide claim surveillance to identify high cost generic, brand and specialty prescription drugs and provide alternate ways to reduce or eliminate drug costs; Pharmaceutical benefit management services; providing healthcare benefits optimization information; Providing financial consultation services in the field of pharmaceutical benefit optimization; Financial administration of pharmacy reimbursements programs and services
Cost management for prescription drug plans of others in the field of pharmaceuticals; business services, namely, prescription drug formulary cost management services; business administration of pharmacy reimbursement program and services; providing pharmaceutical, medication, drug, and healthcare information to physicians and pharmacists regarding costs related to the use of generic and name brand products of others; Business consulting services regarding healthcare costs, benefits and pharmacy services; Drug utilization review services; pharmaceutical cost management services; strategic business analysis and business advice regarding pharmacy benefit management, pharmaceutical end-user behavior, healthcare use behavior; market study and analysis of healthcare, healthcare benefits, and pharmacy benefits effecting health behavior change and choice at the patient level; market analysis and reporting of the effectiveness of tailored health messaging and support at the patient level; prov...
